Mitotane-Induced Hyperlipidemia: A Retrospective Cohort Study

Table 2

Reported HDL-c changes with lipid targeting drugs.

Drug class	Serum HDL-c increase
Bile acid sequestrants	0-1% [17]
Cholesterol absorption inhibitors	1% [18]
HMG-CoA reductase inhibitors	5–10% [9]
Omega-3 fatty acids	5–9% [19]
Estrogen	7–15% [20, 21]
Fibrates	5–20% [8]
Nicotinic acid	15–35% [8, 15]
Fibrates combined with nicotinic acid	up to 45% [15]
Cholesteryl ester transfer protein inhibitors	55–130% [22]